Daniel R Mcmasters

US Patent:

20040229840, Nov 18, 2004

Filed:

Oct 28, 2003

Appl. No.:

10/694677

Inventors:

Balkrishen Bhat - Carlsbad CA, US
Anne Eldrup - Encinitas CA, US
Steven Carroll - Yardley PA, US
David Olsen - Lansdale PA, US
Daniel McMasters - New York NY, US
Malcolm MacCoss - Freehold NJ, US
Jie Xia - Carlsbad CA, US

International Classification:

A61K031/7072
A61K031/513
C 07D 4 9/04

US Classification:

514/050000, 514/269000, 536/028100, 544/317000

Abstract:

The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.

US Patent:

20090099126, Apr 16, 2009

Filed:

Aug 4, 2006

Appl. No.:

11/990051

Inventors:

Gabor Butora - Martinsville NJ, US
Kenneth Alan Koeplinger - Lansdale PA, US
Malcolm MacCoss - Freehold NJ, US
Daniel R. McMasters - New York NY, US
David B. Olsen - Lansdale PA, US
Lihu Yang - Edison NJ, US

International Classification:

A61K 31/7076
C07H 19/16
A61K 31/7064
A61P 31/12
C07H 19/06

US Classification:

514 45, 536 276, 536 285, 514 49

Abstract:

The present invention provides ribonucleoside 2′,3′-cyclic acetals of structural formula I which are precursors or prodrugs of inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors of inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as pre-cursors or prodrugs of inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors or prodrugs of inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such ribonucleoside 2′,3′-cyclic acetals alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the ribonucleoside 2′,3′-cyclic acetals of the present invention.

US Patent:

20170369507, Dec 28, 2017

Filed:

Dec 1, 2015

Appl. No.:

15/532549

Inventors:

- Rahway NJ, US
Stephane L. Bogen - Rahway NJ, US
Matthew L. Childers - Boston MA, US
Francesc Xavier Fradera Llinas - Boston MA, US
Michael J. Ellis - Boston MA, US
Sara Esposite - Neptune NJ, US
Qingmei Hong - Kenilworth NJ, US
Chunhui Huang - Kenilworth NJ, US
Alexander J. Kim - Rahway NJ, US
John W. Lampe - Cary NC, US
Michelle R. Machacek - Boston MA, US
Daniel R. McMasters - Boston MA, US
Ryan D. Otte - Boston MA, US
Michael H. Reutershan - Boston MA, US
Nunzio Sciammetta - Boston MA, US
Patrick Pengcheng Shao - Kenilworth NJ, US
David L. Sloman - Boston MA, US
Feroze Ujjainwalla - Kenilworth NJ, US
Catherine White - Boston MA, US
Zhicai Wu - Kenilworth NJ, US
Yang Yu - Kenilworth NJ, US
Kake Zhao - Kenilworth NJ, US
Craig R. Gibeau - Boston MA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 498/08
C07D 471/04
C07D 498/10
C07D 471/08
A01N 43/00

Abstract:

The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.

US Patent:

20170360800, Dec 21, 2017

Filed:

Dec 1, 2015

Appl. No.:

15/532548

Inventors:

- Rahway NJ, US
Stephane L. Bogen - Rahway NJ, US
Matthew Lloyd Childers - Boston MA, US
Francesc Xavier Fradera Llinas - Boston MA, US
Alexander J. Kim - Rahway NJ, US
John W. Lampe - Cary NJ, US
Michelle R. Machacek - Boston MA, US
Daniel R. McMasters - Boston MA, US
Nunzio Sciammetta - Boston MA, US
Patrick Pengcheng Shao - Kenilworth NJ, US
David L. Sloman - Boston MA, US
Wanying Sun - Kenilworth NJ, US
Feroze Ujjainwalla - Kenilworth NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/5513
C07D 471/14
C07D 471/04
A61K 45/06
C07D 519/00
A01N 43/00

Abstract:

The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I); wherein A is —C(R1)= or —N═; and X is selected from the group consisting of: (II-i), (II-ii), (I) (II-iii), and (II-iv). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.

US Patent:

20170362220, Dec 21, 2017

Filed:

Dec 1, 2015

Appl. No.:

15/532552

Inventors:

- Rahway NJ, US
Stephane L. Bogen - Rahway NJ, US
Matthew L. Childers - Boston MA, US
Francesc Xavier Fradera Llinas - Boston MA, US
Michael J. Ellis - Boston MA, US
Sara Esposite - Neptune NJ, US
Dawn M. Hoffman - Boston MA, US
Chunhui Huang - Kenilworth NJ, US
Solomon D. Kattar - Boston MA, US
Alexander J. Kim - Rahway NJ, US
John W. Lampe - Cary NJ, US
Michelle R. Machacek - Boston MA, US
Daniel R. McMasters - Boston MA, US
Michael H. Reutershan - Boston MA, US
Nunzio Sciammetta - Boston MA, US
Patrick Pengcheng Shao - Kenilworth NJ, US
David L. Sloman - Boston MA, US
Wanying Sun - Kenilworth NJ, US
Feroze Ujjainwalla - Kenilworth NJ, US
Zhicai Wu - Kenilworth NJ, US
Yang Yu - Kenilworth NJ, US
Craig R. Gibeau - Boston MA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 471/04
C07D 519/00
C07D 471/14

Abstract:

The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes (I); wherein A is —C(R)═ or —N═; and X is selected from the group consisting of: (II-i), and (II-ii). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.